Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Biomarin Pharmaceutical Inc

NASDAQ: BMRN · Life Sciences · 7 alerts · CIK 1048477

Share price
$57.99Close, Nov 16
Market cap
$11.2B
Shares outstanding
193.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biomarin Pharmaceutical Inc filings on SEC EDGAR ↗

4:16 PM ET 8-K
Licensing Deal

Biomarin Pharmaceutical Licensing Deal with Ascendis Pharma A/S

BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma, granting Ascendis a non-exclusive worldwide license to certain patents for the commercialization of TransCon CNP (navepegritide). In exchange, BioMarin will receive royalties of 20% on net sales in the U.S. and 18% in the EU, Brazil, and South Korea through May 2030, while both parties agreed to dismiss all pending patent litigation.

Counterparty
Ascendis Pharma A/S
Term
through May 2030

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.